文献速递食管胃疾病与幽门螺杆菌胃肠动力与功能性疾病

pH-阻抗监测反流次数与反流为主GERD患者症状改善及治疗满意度相关

Number of reflux episodes on pH-impedance monitoring associates with improved symptom outcome and treatment satisfaction in gastro-oesophageal reflux disease (GERD) patients with regurgitation.
PubMed 文献 · Gut · 2020-05-28

该研究对152例随机分配至每日两次PPI或磁性括约肌 augmentation(MSA)的反流为主GERD患者进行事后分析,123例有完整数据。治疗后酸暴露时间和反流次数均显著下降,反流次数降至<40次与症状应答及满意度显著相关,ROC分析显示<35次更优。交叉至MSA者治疗前>80次反流可预测改善。

要点

  • pH-阻抗监测反流次数降至生理水平与反流为主GERD患者症状改善和满意度相关。
  • 反流次数<40次与FSQ反流评分、GERD HRQL及满意度应答显著相关,<35次ROC表现更优。
  • 交叉至MSA者治疗前>80次反流可预测症状改善。

核心结论

  • pH-阻抗监测反流次数降至生理水平与反流为主GERD患者症状改善和治疗满意度相关,而病理水平可预测MSA治疗改善。

研究设计与样本

  • 对152例随机分配至每日两次PPI或MSA(2:1)的中重度反流患者进行事后分析,123例有完整pH-阻抗数据。
  • 症状应答定义为FSQ反流评分改善至无或轻微、GERD HRQL评分下降≥50%及治疗满意。

主要发现

  • MSA组症状和满意度评分较每日两次PPI显著改善。
  • 酸暴露时间从13.4%±0.7%降至1.3±0.2%(p<0.001),反流次数从86±4降至48±4(p<0.001)。
  • 反流次数降至<40次在FSQ反流评分、GERD HRQL评分和满意度应答者中更常见(每项p≤0.03)。
  • ROC分析显示<35次反流表现更优。
  • 交叉至MSA者治疗前>80次反流预测改善。

关键数值与推荐

  • 反流次数<40次与症状应答和满意度显著相关(p≤0.03)。
  • ROC分析显示<35次反流阈值表现更优。
  • 交叉至MSA者治疗前>80次反流预测改善。

临床怎么用

  • 对反流为主GERD患者,pH-阻抗监测反流次数可用于评估治疗应答和指导治疗选择。
  • 反流次数降至<40次(尤其<35次)可作为治疗目标参考。
  • 考虑MSA治疗时,治疗前>80次反流可能提示更易获益。

局限性

  • 事后分析,样本量有限(123例完整数据)。
  • 研究人群为反流为主且中重度症状患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Number of reflux episodes, an adjunctive metric on pH-impedance monitoring, is incompletely studied. We aimed to determine if number of reflux episodes associates with therapeutic outcome in regurgitation predominant gastro-oesophageal reflux disease (GERD). DESIGN: We performed post hoc analysis of postintervention pH-impedance data from adult patients with moderate/severe regurgitation despite QD proton pump inhibitor (PPI), randomised to either two times a day PPI or magnetic sphincter augmentation (MSA) in 2:1 allocation. After 6 and 12 months, symptom response was defined by improvement in Foregut Symptom Questionnaire (FSQ) regurgitation score to none or minimal, ≥50% reduction in GERD health-related quality of life (HRQL) score and satisfaction with therapy. Univariate and multivariate analyses were performed to determine predictors of symptom improvement. RESULTS: Of 152 randomised patients, 123 (age 46.9±1.2 year, 43% female) had complete data. Symptom and satisfaction scores significantly improved after MSA compared with two times a day PPI. Both acid exposure time (13.4%±0.7% to 1.3±0.2%, p<0.001) and reflux episodes (86±4 to 48±4, p<0.001) declined with therapy. Reduction to <40 reflux episodes was significantly more frequent in those with symptom response by FSQ regurgitation score, GERD HRQL score and satisfaction with therapy (p≤0.03 for each); <35 episodes performed better on receiver operating characteristic analysis. On multivariate analysis, improvement in regurgitation score remained independently predictive of satisfaction with therapy (p<0.001 for each). In patients crossing over to MSA, >80 episodes pretreatment predicted improvement. CONCLUSIONS: Reduction of reflux episodes on pH-impedance to physiological levels associates with improved outcomes, while pathological levels predict improvement with MSA in regurgitation predominant GERD. TRAIL REGISTRATION NUMBER: ClinicalTrials.gov: NCT02505945.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Rogers BD, Valdovinos LR, Crowell MD, et al. Number of reflux episodes on pH-impedance monitoring associates with improved symptom outcome and treatment satisfaction in gastro-oesophageal reflux disease (GERD) patients with regurgitation. Gut. 2020. PMID: 32467089. doi:10.1136/gutjnl-2020-321395

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。